The novel antiepileptic drug (AED) levetiracetam (LEV, Keppra ® ) is indicated as adjunctive therapy for partial epilepsy. The primary aim of this study was to measure the safety and tolerability of LEV individualised dosing in a heterogeneous refractory epilepsy population. Methods: LEV was evaluated in a 10-to 16-week open-label, multicentre study in adult patients with epilepsy refractory to previous treatment with at least two AEDs. Individualised LEV doses up to 3000 mg day −1 were determined in an initial up-titration phase, and optimal doses were administered as adjunctive treatment during an 8-to 10-week evaluation period. Concomitant AEDs and their doses could not be changed during the study. Safety and tolerability were monitored by expression of adverse events as well as by retention rate. The effect of LEV on concomitant AED concentration was also studied. Efficacy was assessed using global clinical evaluation (GCE) scores, seizure frequency, and ≥50% responder rate. Results: LEV therapy was initiated in 219 patients; 183 had localisation-related epilepsy and 37 had generalised epilepsy. In one patient, epileptic syndrome was defined as both localisation-related and generalised. About 81.7% (179/219) continued and completed treatment throughout the study, and 79% (172/219) chose to continue LEV in a follow-up study. The most common adverse events were asthenia, dizziness, and somnolence. Most adverse events occurred during up-titration. LEV treatment did not alter the concentration of concomitant AEDs. LEV improved GCE scores in 79.5% (152/191) of patients. LEV reduced the median total seizure frequency of all patients from a median of 2.25 seizures per week at baseline (n = 219) to 1.10 seizures per week during the evaluation period (n = 191 patients with at least one seizure count during evaluation). The ≥50% responder rate was 48.2% for all seizure types, 49.4% for partial-onset, and 51.4% for generalised-onset seizures. Throughout the evaluation period (i.e. from the start of the evaluation period until completion or early discontinuation), 26/191 (13.6%) had a 100% reduction in total seizure frequency, while in a follow-up study, 10.5% (18/172) were seizure-free for at least 6 months and 6.4% (11/172) were seizure-free for at least 1 year. Conclusion: LEV was well tolerated, as evidenced by limited adverse event reporting and the high retention rate, and appeared effective in both generalised and partial epilepsy.
INTRODUCTION
Levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide; Keppra ® ; Keppra is a registered trademark of UCB S.A.) is an antiepileptic drug (AED) approved for marketing in 28 countries, including the US, European Union, and Australia, as an adjunct treatment for partial epilepsy. Levetiracetam is rapidly and almost completely absorbed following oral administration and exhibits near linear pharmacokinetics 1 . Interactions with other drugs are unlikely, since levetiracetam has minimal protein binding and is neither metabolised by nor interacts with specific hepatic enzymes. Minimal metabolism to an inactive metabolite occurs, and both compounds are excreted in urine 1, 2 . Levetiracetam has a half-life of 6-8 hours, allowing for twice-daily dosing 1, 3 .
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown; however, the mechanism of action appears to differ from that of other AEDs 4 . Levetiracetam does not modulate Na + and T-type Ca 2+ channels 5 and does not induce any conventional modulation of the GABAergic system 6 or ionotropic excitatory glutamate receptors 7 . Levetiracetam has been shown to potently antagonise negative modulators of both GABA and glycine receptors 6 . Other potential mechanisms underlying its antiepileptic action involve inhibition of high voltage-activated calcium currents 8 and a moderate suppression of the delayed rectifier K + current 9 . Levetiracetam's antiepileptic effect may relate to an interaction with a brain-specific binding site 10 .
Levetiracetam's potential as a broad-spectrum AED with a wide margin of safety was apparent from animal models of partial and generalised epilepsy [11] [12] [13] [14] .
Results from phase II clinical trials evaluating levetiracetam as add-on therapy in patients with refractory partial and/or secondarily generalised seizures demonstrated that doses up to 4000 mg day −1 are effective and well tolerated 15, 16 . The antiepileptic efficacy and tolerability of levetiracetam were confirmed in phase III studies, in which patients with refractory partial seizures with or without secondary generalisation received 1000, 2000, or 3000 mg day −1 as adjunctive therapy or were converted to monotherapy [17] [18] [19] . Levetiracetam significantly reduced seizure frequency regardless of seizure subtype.
The objective of this study was to add patient exposure, regardless of seizure type, to the safety database. In addition, this study was designed to obtain a standardised descriptive evaluation of the safety and efficacy of levetiracetam at individualised doses up to 3000 mg day −1 in patients with refractory epilepsy.
METHODS

Study design
In this multicentre, noncomparative, open-label phase III study, individualised doses of levetiracetam were evaluated in patients who were refractory to previous treatment with at least two AEDs. The study consisted of a 4-week retrospective baseline, a 2-to 6-week up-titration, and an 8-to 10-week evaluation period. This study followed Good Clinical Practice, the Declaration of Helsinki, and was supervised by an Independent Ethics Committee.
All patients initially received 1000 mg day −1 of levetiracetam (500 mg b.i.d. orally), which was manufactured and packaged by UCB S.A., Brussels. The dose was up-titrated at clinic visits every 2 weeks in steps of 1000 mg day −1 up to a maximum of 3000 mg day −1 , until an optimal individualised evaluation dose of 1000, 2000, or 3000 mg day −1 was achieved. Optimal doses were determined based on improvement in seizure expression and absence of substantial adverse events. If no remarkable improvement in seizure control occurred and there were no significant drug-related adverse events at lower doses, 3000 mg day −1 of levetiracetam was considered the optimal dose. The duration of the up-titration period was 2-6 weeks, depending on how quickly an effective dose was reached. After every visit during the titration period, the investigator could decide to titrate upwards from 1 to 2 g or from 2 to 3 g, if seizures were still occurring and no adverse effects were seen. The investigator could down-titrate from 3 to 2 g or from 2 to 1 g if there were unacceptable adverse effects. Patients could enter the evaluation period without further titration if a marked improvement had been experienced and no significant adverse effects were seen, or if the patient did not wish to make additional changes.
During the 8-to 10-week evaluation period, patients received their individualised optimal levetiracetam dose as an adjunct to their stable regimen of concomitant AED therapy. Patients who wanted to terminate treatment entered a variable period of gradual withdrawal in which the levetiracetam dose was reduced by no more than 1000 mg every 3-7 days. A final clinical evaluation was undertaken 2 weeks following the termination of treatment. After completion of the evaluation period, patients were given the option of entering a continuation study.
Patient selection
Patients aged 16-70 years were eligible for this study if they had uncontrolled seizures that were classifiable according to the International Classification of Epileptic Seizures and treated with at least one and at most three concomitant AEDs at a stable dose regimen for at least 4 weeks prior to study initiation. Patients with either partial-onset seizures or generalised seizures were included. Female patients of childbearing potential were accepted only if adequate birth control measures were followed. Patients were excluded from this study if they were taking tiagabine or felbamate as standard AED treatment, barbiturates (except phenobarbital), benzodiazepines, or any medication that could affect CNS function (with the exception of approved AEDs). Tiagabine was excluded because of a lack of ability to assay plasma levels. Felbamate was excluded because of the potential risk of aplastic anaemia and hepatic failure 20 .
Patients were also excluded if they had a history of psychiatric disorder, drug or alcohol abuse, severe or multiple drug allergies, impaired hepatic or renal function, clinically significant disease, or cerebrovascular accident or cerebral tumours. Pregnant or lactating patients were excluded, as were patients participating in another clinical trial within 8 weeks of the start of the study or any time during the study. Patients could discontinue the study if they failed to comply with the protocol or drug treatment regimens, if they wished to terminate treatment, if the study treatment failed to prove beneficial, or if adverse events were sufficiently severe. All patients gave written informed consent prior to any study-specific procedures.
Data collection
Safety
Clinical assessments included medical histories as well as physical and neurological examinations at each visit. The incidence, nature, and severity of adverse events and their relationship to levetiracetam were recorded. Adverse events were classified according to Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART). Laboratory tests, including blood (20 ml) and urine samples (midstream), were conducted at each visit, and 12-lead ECGs were conducted at the beginning and the end of study participation. Samples were analysed for standard haematology, blood and serum chemistry, and urinalysis measures. Trough plasma levels of levetiracetam, concomitant AEDs, and metabolites were analysed at every visit from blood samples taken approximately 12 hours post-dose.
Efficacy
Efficacy was measured by the global clinical evaluation (GCE) scale as well as seizure counts. Patients were rated as clearly improved (4), improved (3), stable (2), worsened (1), or clearly worsened (0) compared to the pretrial period and selection visit, and results were reported as a percentage of patients.
The total number of seizures per patient and the number per seizure type were also recorded. Seizure counts were determined from patient self-reporting on daily report cards containing the date and time of onset, number of seizures, and description of seizures. Responder rates were calculated as the percentage of patients who showed a reduction of 50% or more in seizure frequency per week compared to the 4-week retrospective baseline. Responder rates were calculated for total seizures, for partial-onset and generalised seizures, and for patient subgroups based on concomitant AED.
Statistical analysis
Safety analysis was performed on a total of 219 patients in the intent-to-treat population who received at least one dose of levetiracetam. Efficacy analysis was performed on patients who completed the titration period and had at least one assessment in the evaluation period. Safety and efficacy data were assessed using descriptive statistics, including mean and standard deviation, and median with minimum and maximum. The number and percentage of patients who reported adverse events was tabulated by study period, body system, COSTART preferred term, severity, and relationship to treatment.
RESULTS
Patient characteristics and disposition
This study was initiated in January 1998 and completed in October 1998. A total of 232 patients from 13 centres in Europe and the United States were screened; 219 received at least one dose of levetiracetam. A total of 191 patients completed the titration and entered the evaluation period. The disposition of patients throughout the study is illustrated in Fig. 1 .
The study population consisted primarily (95%) of Caucasians and included approximately equal numbers of men (52%) and women (48%). The mean age of patients in the study was 36 ± 13 years ( Table 1) . The aetiology of epilepsy was unknown for 43.8% (96/219) of the patients, whereas it was determined to be genetic in 11.9% (26/219), caused by cranial trauma in 11.4% (25/219), and due to cerebral infection in 9.1% (20/219). The mean age at epilepsy onset was 12 ± 11 years, and the mean duration of epilepsy was 24 ± 13 years. About 183 patients had localisation-related epilepsy and 37 patients had generalised epilepsy. In one patient, epileptic syndrome was defined as both localisation-related and generalised.
Of the patients with generalised epilepsy, 32% (12/37) were diagnosed by the investigator as having juvenile myoclonic epilepsy. Four others (11%) had a combination of myoclonic and absence seizures with or without generalised tonic-clonic seizures. This combination of seizure types suggests juvenile myoclonic epilepsy, even though this syndrome diagnosis was not specifically stated. One patient was diagnosed with juvenile absence epilepsy. Three patients (8.3%) had isolated generalised tonic-clonic seizures. Four patients (11%) were diagnosed with Lennox-Gastaut Syndrome, and four others (11%) were diagnosed with symptomatic generalised epilepsy, not further specified. In the eight remaining patients with generalised epilepsy, further epilepsy classification was not specified. A history of status epilepticus was reported in 23.7% of all patients.
At the last visit, 121 (55.3%) patients were taking >2000-3000 mg day −1 of levetiracetam, 56 (25.6%) were taking >1000-2000 mg day −1 , 39 (17.8%) were taking ≤1000 mg day −1 , and three (1.4%) were taking >3000-4000 mg day −1 . The most common concomitant AEDs (given to >10% of patients) were carbamazepine (47.0%), lamotrigine (41.1%), topiramate (25.1%), valproate (27.9%), phenytoin (22.8%), and gabapentin (19.6%).
Tolerability and safety
A total of 196 of 219 patients (89.5%) reported treatment-emergent adverse events. The frequency of adverse events did not appear to be dose-dependent ( Table 2) . The patient population receiving the lowest dose of levetiracetam (1000 mg) (at the end of the study) exhibited the highest percentage of those adverse events most frequently reported (asthenia, dizziness, somnolence, and nervousness). There was no apparent correlation between the distribution of adverse events and specific concomitant AEDs. Adverse events were most prevalent early in the study: 81.8% of patients reported adverse events during up-titration, 66.3% during the evaluation phase, and 22.6% during down-titration. The most common adverse events in all three dosage groups were asthenia, dizziness, and somnolence (Table 2) . A total of 31 of 219 patients (14.2%) had adverse events that led to the discontinuation of levetiracetam treatment, most commonly (27 patients) during up-titration. Convulsion was the most common reason for withdrawal (13/31; 42%).
Treatment-emergent behavioural adverse events included nervousness (21/219; 9.6%), depression (16/219; 7.3%), hostility (9/219; 4.1%), personality disorder (8/219; 3.7%), emotional liability (6/219; 2.7%), anxiety (5/219; 2.3%), psychosis (2/219; 0.9%), agitation (2/219; 0.9%), euphoria (2/219; 0.9%), suicide attempt (1/219; 0.5%), and hallucinations (1/219; 0.5%). (Some patients reported more than one.) Most of these events were mild or moderate in severity. They were severe in seven patients (three patients with symptoms of hostility and one patient each with symptoms of depression, nervousness, personality disorder, and psychosis). The severe symptoms of psychosis, depression, and nervousness were considered to be possibly related to levetiracetam treatment, and one expression of hostility was considered probably related to treatment. Two severe events of hostility and one severe event of personality disorder were considered to be unlikely related to levetiracetam. At the time of the suicide attempt, the patient was taking 2000 mg day −1 . All other behavioural adverse events occurred with similar frequency across all doses (≤1500, >1500 to ≤2500, >2500 to ≤3500 mg day −1 ). Seven patients discontinued levetiracetam because of behavioural adverse events. Reasons for withdrawal included psychosis Adverse event ≤1000 mg day −1 (n = 39) >1000 to ≤2000 mg day −1 (n = 56) >2000 to ≤3000 mg day −1 (n = 121) (two patients), attempted suicide (one patient), and anxiety, depression, hostility, and personality disorder (one patient each). In most cases no action was required; patients fully recovered. There were no clinically meaningful changes in physical and neurological examination or in ECG throughout the study. Vital signs did not change significantly over the study period.
Laboratory measures
Plasma levels of concomitant AEDs were not changed by the addition of levetiracetam. Mean trough plasma levels (µg ml −1 ± SD) prior to levetiracetam treatment, during up-titration, and during evaluation are shown in Table 3 .
There was little or no change from baseline in the mean laboratory values for all parameters during the study; values were generally within the normal range. The white blood cell count was decreased in nine patients and increased in one patient. Urinalysis values showed elevated white or red blood cell counts in nine and fourteen patients, respectively, and elevated protein concentrations in two patients. However, none of these values were considered to be clinically significant and none warranted the termination of levetiracetam.
Efficacy
Global clinical evaluation (GCE)
Of the 191 patients who had a GCE score at baseline and during the evaluation period, 152 (79.5%) showed improvement following treatment with levetiracetam (GCE rating of 3 or 4). Nine (4.7%) patients worsened (GCE rating of 1). When patients were evaluated by seizure type, 78.9% (127/161) with partial-onset seizures and 80.6% (25/31) with generalised-onset seizures showed improvement in the GCE at the end of the evaluation period compared to baseline. Fig. 2 shows the GCE scores according to the last levetiracetam dose. The median GCE score at all visits during the up-titration and the evaluation period for all patients was 3 (improved).
Median seizure frequency
Seizure frequency was evaluated on the population with at least one seizure of the type analysed during baseline or with at least one assessment during evaluation. Levetiracetam reduced the median total seizure frequency of all patients from a median of 2.25 (range = 0-125) seizures per week at baseline (n = 219) to 1.10 (range = 1-105) seizures per week during the evaluation period (n = 191 patients with at least one seizure count during evaluation). Seizure frequency was also evaluated separately by seizure type for patients with partial-onset or generalised-onset seizures on the subsets of patients with at least one seizure during baseline or the evaluation period. In patients presenting with partial-onset seizures, the median seizure frequency was reduced from 2.00 (range = 0-76, n = 186) to 1.05 (range = 0-62, n = 158) seizures per week. In patients with generalised-onset seizures at baseline and/or during the evaluation period, the median seizure frequency was reduced from 1.50 (range = 0-125, n = 65) seizures per week to 1.30 (range = 0-105, n = 37) seizures per week. (Out of the 65 patients included in this subset, 21 discontinued before entering the evaluation period and seven had missing seizure frequency per week assessments for the evaluation period. Therefore, these could not be included in the seizure frequency per week calculation.)
Responder rate
The responder rate was defined in the population with at least one seizure count of the analysed type during baseline or evaluation and at least one assessment during the evaluation period. The responder rate, or percentage of patients with a ≥50% reduction in seizure frequency, was 48.2% (92/191) for all seizure types, 49.4% (78/158) for patients with partial-onset seizures, and 51.4% (19/37) for patients Table 4 : Responder rate over the evaluation period.
Total (N = 219), Levetiracetam dose at end of study % (n) ≤1000 mg day −1 >1000-≤2000 mg day −1 >2000-≤3000 mg day −1 >3000-≤4000 mg day a All patients with at least one assessment during evaluation; b All patients with at least one seizure of the analysed type during baseline or evaluation and at least one assessment during evaluation. Table 5 : Responder rate by concomitant antiepileptic drug (intent-to-treat population).
All seizure types, % (n) Partial-onset, % (n) Generalized-onset, % (n) with generalised seizures. Table 4 shows the responder rate by final dosage. The number and percentage of responders by seizure type and the most common concomitant AED treatment are shown in Table 5 .
The data further showed that 59 of 191 patients (30.9%) with all seizure types had at least a 75% reduction in total seizure frequency, and that 26 (13.6%) had a 100% reduction in total seizure frequency, becoming seizure-free throughout the evaluation period (i.e. from the start of the evaluation period until completion or early discontinuation). Among patients with partial-onset seizures, 31% (49/158) had at least a 75% reduction in seizure frequency and 16.5% (26/158) became seizure-free. Among those with generalised-onset seizures, 40.5% (15/37) had at least a 75% reduction in seizure frequency, and 8% (3/37) became seizure-free.
Long-term follow-up
After completion of the evaluation period, patients could enter a follow-up study. Long-term follow-up was not analysed as a separate study, but patients were entered in the database that consisted of all patients ever exposed to levetiracetam during the development program (n = 1422). The cut-off date for analysis was June 1999, because follow-up was discontinued upon registration of levetiracetam 21 . Of the 179 patients who completed evaluation in the initial study, 172 (96%) chose to continue adjunctive levetiracetam treatment. The median duration of levetiracetam exposure in patients entering the follow-up study was 391 days (range = 95-563). During follow-up, the dose of levetiracetam was increased in 55.8% (96/172) of patients. This included 15/21 patients whose last dose in the initial study had been ≤1000 mg, 29/46 whose last dose had been >1000 but ≤2000 mg, and 52/102 whose last dose had been >2000 but ≤3000 mg.
During follow-up, 21.5% (37/172) of patients had a change in concomitant AED therapy. In 11.6% (20/172), another AED was added to the treatment regimen. Concomitant AED therapy was stopped in 11% (19/172) of patients. (In two patients, an AED was both stopped and added.)
Among patients entering the follow-up study, 10.5% (18/172) were seizure-free for at least a 6-month period during their total exposure (initial study and follow-up). In the same subset of the population, 6.4% (11/172) of patients were seizure-free for at least a 1-year period during their total exposure (initial study and follow-up). In patients receiving treatment for longer than 1 year, 13.2% (18/136) were seizure-free for a period lasting at least 6 months, and 8.1% (11/136) were seizure-free for at least 1 year.
DISCUSSION
The primary goal of this study was to determine the safety and tolerability of optimised doses of levetiracetam when given as an adjunct treatment. A sensitive measure of short-term tolerability is continuation rate. The retention rate for levetiracetam was high (81.7%; 179/219) throughout the initial study. In addition, 96% (172/179) of patients completing the study chose to continue levetiracetam in a follow-up study. Long-term retention rates were similar to those previously described 21 . The most common adverse events attributed to treatment, asthenia, somnolence, and dizziness, were also experienced by patients in other double-blind clinical studies of levetiracetam 15, [17] [18] [19] . The adverse events experienced by patients in Europe and the USA were similar in nature and extent. The frequency of adverse events was not correlated with the final dose. Contrary to expected dose-response effects, patients receiving the lowest dose of levetiracetam at the end of the study exhibited the highest percentage of those adverse events most frequently reported (asthenia, dizziness, somnolence, and nervousness). This tendency may reflect an increased likelihood of patients to remain at or to go back to a lower dosage if they are having difficulty tolerating levetiracetam. The majority of patients received higher dosages and exhibited lower frequencies of adverse events. The majority of adverse events occurred early in treatment, during up-titration. These findings suggest that adverse events are triggered by the initial exposure to levetiracetam but abate over time. Therefore, we would expect that after an initial adjustment to levetiracetam treatment, adverse events would not be common.
Behavioural adverse events were somewhat higher than in double-blind clinical trials. However, behavioural adverse events were each reported in less than 10% of the treated population, and many of them were reported in less than 1%. The most common events included nervousness and depression. The overall incidence of these events was relatively low and did not require discontinuation of treatment in most cases. It is encouraging that behavioural events had a low incidence, did not usually require the discontinuation of levetiracetam, and were not dose-dependent.
There was little or no change in blood or urinalysis laboratory values for all parameters tested. Changes in white blood cell counts and red blood counts were not clinically significant. There were no clinically meaningful changes in physical and neurological examination or in ECG during the study. Also, consistent with levetiracetam's pharmacokinetic profile, levetiracetam treatment did not alter the mean trough plasma levels of concomitant AEDs. Although this study was not specifically designed to test efficacy, levetiracetam markedly reduced seizure frequency for both partial and generalised seizures. The responder rates were approximately 50% for partial-onset and generalised-onset seizure subgroups for most doses tested, suggesting that similarly effective individual dosages were achieved in all groups. A total of 79.5% of patients experienced improvement in their GCE score after levetiracetam treatment. Of the 191 patients who entered the evaluation period and had evaluable efficacy measurements, 13.6% were seizure-free from the start of the evaluation period until completion or early discontinuation. The most clinically relevant indicator of efficacy is the duration of seizure freedom. When pooling this study with the long-term follow-up treatment of patients, 10.5% of patients were seizure-free for at least 6 months and 6.4% were seizure-free for at least 1 year. These results show that levetiracetam compares very favourably with new potent AEDs in rendering patients seizure-free with optimised doses, with few discontinuations due to adverse events 22, 23 .
The results from this multicentre trial demonstrate that levetiracetam has a favourable safety profile when administered at optimised doses ranging from 1000 to 3000 mg day −1 . In addition, levetiracetam reduced seizure frequency in both partial and generalised seizures. A high percentage of patients became seizure-free for a clinically relevant period of more than 6 months. Randomised controlled trials of levetiracetam efficacy in generalised-onset seizures are indicated.
